SAMHSA-HRSA CENTER for INTEGRATED HEALTH SOLUTIONS

Best Practices in Hepatitis Prevention and Care

August 11, 2015

Jhilya Mayas, PhD
Technical Vice President
The MayaTech Corporation
Learning Objectives

Participants will be able to:

• Understand the burden of viral hepatitis in the US
• Describe the populations at risk for viral hepatitis
• Understand viral hepatitis screening recommendations
• Describe key barriers to identifying individuals with viral hepatitis and engaging them in care
• Discuss effective strategies and tools for addressing viral hepatitis
Viral Hepatitis – The Silent Epidemic

Viral hepatitis is caused by one of 5 distinct viruses Transmitted through the fecal-oral route (hepatitis A) or blood exposure (hepatitis B, C)

Over 5 million individuals in the US are infected with viral hepatitis and many are undiagnosed and unaware

- Asymptomatic disease
- Stigma
- Low prioritization by clinicians
- Ineffective treatment options

Hepatitis A, B, and C Are Distinct Viruses

Hepatitis A virus (HAV)
- <2,000 new cases in the US annually;
- Preventive vaccine available – often recommended for travel overseas

Hepatitis B virus (HBV)
- ~1 million chronically infected in the United States; 5,000 deaths annually
- Preventive vaccine available

Hepatitis C virus (HCV)
- > 3 million chronically infected in the US
- Can be cured with treatment with new drugs
- NO available vaccine

http://www.cdc.gov/hepatitis/
Hepatitis B and C Have Distinct Treatment Goals

Hepatitis B virus (HBV) is **NOT** curable with current therapy; treatment goal is long-term viral suppression
- This goal is similar to that in HIV

Hepatitis C virus (HCV) is **curable**; currently available therapies have cure rates >95%

- HIV 1.1 million
- HCV 3.2 million
- HBV 1.1 million
# HBV and HCV Routes of Transmission

<table>
<thead>
<tr>
<th>Routes of Transmission</th>
<th>Hepatitis B</th>
<th>Hepatitis C</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Contact with infectious blood, semen, and other bodily fluids primarily through:</td>
<td>Contact with blood of an infected person primarily through:</td>
</tr>
<tr>
<td></td>
<td>• Birth to an infected mother</td>
<td>• Sharing contaminated injection drug equipment</td>
</tr>
<tr>
<td></td>
<td>• Sexual contact with infected person</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sharing contaminated injection drug equipment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Needlesticks</td>
<td></td>
</tr>
</tbody>
</table>

Source: The ABCs of Hepatitis, [http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable_BW.pdf](http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable_BW.pdf)
## HBV and HCV Persons at Risk

<table>
<thead>
<tr>
<th>Persons at Risk</th>
<th>Hepatitis B</th>
<th>Hepatitis C</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Sex partners of infected persons</td>
<td>• People who use injection drugs (current or former)</td>
</tr>
<tr>
<td></td>
<td>• Persons with multiple sex partners</td>
<td>• People living with HIV</td>
</tr>
<tr>
<td></td>
<td>• Persons with STIs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Men who have sex with men</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• People who use injection drugs</td>
<td></td>
</tr>
</tbody>
</table>

Source: The ABCs of Hepatitis, [http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable_BW.pdf](http://www.cdc.gov/hepatitis/Resources/Professionals/PDFs/ABCTable_BW.pdf)
Hepatitis and PWHA

- Of the 1.1 million PWHA in the U.S., one-third are co-infected with hepatitis
  - 25% co-infected with HCV
  - 10% co-infected with HBV
- 80% of people with HIV who use injection drugs are co-infected with HCV

Management of HBV Infection: Epidemiology, Screening, and Vaccination Strategies
Current Hepatitis B Virus (HBV) Infection Among the U.S. Population

- An estimated 1.4 million people living with chronic HBV infection (2013)
- 3,050 reported acute hepatitis B cases in 2013
  - Incidence rate of 1.0 cases per 100,000
- Estimated 19,800 new HBV infections in 2013
  - Many HBV infections are asymptomatic or unreported
- Rates are highest among males 25-44
- 1 in 12 Asian Americans and Pacific Islanders are infected

Source: Viral Hepatitis Surveillance, United States 2013,
http://www.cdc.gov/features/AAPIHepatitisB/
http://www.samhsa.gov/integration
Figure 3.4. Incidence of acute hepatitis B, by race/ethnicity — United States, 2000–2013

Source: National Notifiable Diseases Surveillance System (NNDSS)
A total of 3,050 case-reports of acute hepatitis B were received in 2013.† More than one risk exposure/behavior may be indicated on each case-report.§

A total of 1,873 acute hepatitis B cases were reported among males in 2013.

Source: National Notifiable Diseases Surveillance System (NNDSS)
Impact of HBV Infection

• HBV is 50-100 times more infectious than HIV
• Acute HBV infection decreased by 62% from 2000 to 2013
  *Increased by 5.4% from 2012 to 2013 (mostly between 30-49 year olds)
• 15-25% of people with chronic HBV infection develop serious liver problems (e.g., liver damage, cirrhosis, liver failure, liver cancer)
• Approximately 3,000 die annually from hepatitis B-related liver disease
Screening Recommendations for HBV

- People who use injection drugs
- Men who have sex with men
- Needle-sharing or sexual partners of persons infected with HBV
- PWHA
- Persons born in regions with high rates of HBV
- All pregnant women
HBV Prevention Through Vaccination

• HBV Vaccination Recommendations
  • Sexual partners of persons with HBV
  • People with multiple sex partners
  • People with STIs
  • Men who have sex with men
  • People who use injection drugs
  • All infants at birth
  • PWHA
Attainable Goal: Elimination of Mother-to-Child Transmission of HBV

• Most new HBV infections in immune-competent adults are resolved by the immune system and do not develop into chronic infection

• Most HBV infections in infants DO develop into chronic infection
Barriers to HBV Screening and Vaccination

- Awareness
- Target population identification
- Cultural/language barriers
- Perception of risk/low prioritization
- Interpretation of HBV screening results
  - Hepatitis B blood panel is comprised of 3 tests
- Completion of HBV vaccine series
  - 2 to 4 doses for adults and children
Health Consequences of HIV / HBV Co-Infection

- Higher levels of HBV DNA
- Rapid liver disease progression
- Lower rates of HBV clearance
- Increased risk of liver-related mortality
- Decreased response to HBV treatment
- Higher risk of hepatotoxicity following ART initiation
- Little effect on HIV disease progression
Group Discussion

Questions/Prompts TBD (Close of business Aug 7th)
Resources for HBV Screening and Vaccination

- **Hepatitis B Foundation** – [www.HepB.org](http://www.HepB.org)
- **CDCs Know Hepatitis B Campaign** – [http://www.cdc.gov/knowhepatitisB/](http://www.cdc.gov/knowhepatitisB/)
- **CDC’s Hepatitis B Professional Resources** – [http://www.cdc.gov/hepatitis/hbv/profresourcesb.htm](http://www.cdc.gov/hepatitis/hbv/profresourcesb.htm)
- **CDC’s Adult Hepatitis B Vaccination Guidelines and Recommendations** – [http://www.cdc.gov/hepatitis/hbv/vaccadults.htm](http://www.cdc.gov/hepatitis/hbv/vaccadults.htm)
Management of HCV Infection: Epidemiology, Screening, and Treatment Approaches
HCV Can Be Cured!
Impact of HCV Infection

• Approximately 3.2 million in the US are chronically infected; HCV is the most common blood-borne infection in the United States
  • 45-85% of those infected are unaware of infection
• 250% increase in acute HCV infection between 2010 and 2013
• For every 100 people infected with HCV:
  • 75-85 develop chronic infection
  • 60-70 develop chronic liver infection
  • 5-20 develop cirrhosis
  • 1-5 will die from liver cancer or cirrhosis

Chronic HCV Infection Reduces Life Expectancy to A Similar Degree as Smoking Tobacco

Reduction in overall life expectancy:
- HCV infection = 8 to 12 years
- Smoking = 13 to 14 years

Figure 4.4. Incidence of acute hepatitis C, by race/ethnicity — United States, 2000–2013

Source: National Notifiable Diseases Surveillance System (NNDSS)
A total of 2,138 case reports of acute hepatitis C were received in 2013.
† More than one risk exposure/behavior may be indicated on each case-report.
§ Risk data not reported.
¶ A total of 1,142 acute hepatitis C cases were reported among males in 2013.
Source: National Notifiable Diseases Surveillance System (NNDSS)
Recommendations for HCV Screening

- One time screening test for persons born 1945-1965
- Major risk - past or present injection drug use
- Other risks
  - Received blood/organs prior to June 1992
  - Received blood products made prior to 1987
  - Ever on chronic hemodialysis
  - Infants born to HCV infected mothers
  - Intranasal drug use
  - Unregulated tattoo
  - History of incarceration
- Medical
  - Persistently elevated ALT (liver enzymes)
  - HIV infection (annual testing)

The HCV Care Continuum

<table>
<thead>
<tr>
<th>Stage</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic HCV-Infected*</td>
<td>100%</td>
</tr>
<tr>
<td>Diagnosed and Aware†</td>
<td>50%</td>
</tr>
<tr>
<td>Access to Outpatient Care†</td>
<td>43%</td>
</tr>
<tr>
<td>HCV RNA Confirmed§</td>
<td>27%</td>
</tr>
<tr>
<td>Underwent Liver Biopsy¶</td>
<td>17%</td>
</tr>
<tr>
<td>Prescribed HCV Treatment¶</td>
<td>16%</td>
</tr>
<tr>
<td>Achieved SVR**</td>
<td>9%</td>
</tr>
</tbody>
</table>

* Chronic HCV-Infected; N=3,500,000.
† Calculated as estimated number chronic HCV-infected (3,500,000) x estimated percentage diagnosed and aware of their infection (49.8%); n=1,743,000.
‡ Calculated as estimated number diagnosed and aware (1,743,000) x estimated percentage with access to outpatient care (86.9%); n=1,514,667.
§ Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage HCV RNA confirmed (62.9%); n=952,726.
¶ Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage who underwent liver biopsy (38.4%); n=581,632.
¶¶ Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage prescribed HCV treatment (36.7%); n=555,883.
** Calculated as estimated number prescribed HCV treatment (555,883) x estimated percentage who achieved SVR (58.8%); n=326,859.

Note: Only non-VA studies are included in the above HCV treatment cascade.

HCV Treatment as prevention?

New treatments may cure more than 95% of patients
- They are well-tolerated and safe, and treatment is only 8-24 weeks
- New treatments are expensive, but studies have shown that they are cost-effective

However, currently only 1-2% of PWID with chronic HCV infection are treated each year

Curing HCV infection in PWID will help prevent new HCV infections
- It will reduce the number of infectious carriers
- With fewer carriers, syringe access and OST programs will be more effective

However, HCV treatment alone will not control HCV infection in PWID
- Combined HCV prevention – syringe access and OST – must be continued (and expanded)
Barriers to HCV Screening and Treatment

- Awareness
- Target population identification
- Perception of risk/low prioritization
- Concomitant risk behaviors
- Need for confirmatory testing
- Perceptions of treatment
- Access to treatment
Current Epidemic of HCV Among Young PWID

Health Consequences of HIV / HCV Co-Infection

• Leading cause of morbidity and mortality among PWHAs
• Increased HCV viral load
• Increased hepatitis C disease progression
• Tripled risk of developing liver disease, liver failure, and liver-related death
• Increased chance of sexually transmitting HCV
Group Discussion

Questions/Prompts TBD (Close of business Aug 7th)
Tools to Support Viral Hepatitis Activities
Comprehensive Strategies to Addressing Viral Hepatitis

Prevention
- Increase provider and public awareness
- Address risk behaviors
- Vaccination

Screening & Diagnosis
- Routinize screening protocols
- Ensure confirmatory diagnoses
- Support healthy behaviors

Treatment
- Link the diagnosed to care
- On-treatment support
- Comorbidity management
- Prevent re-infection (HCV)
U.S. Viral Hepatitis Action Plan (Updated 2014-2016)

- Educating providers and communities to reduce health disparities
- Improving testing, care, and treatment to prevent liver disease and cancer
- Strengthening surveillance to detect viral hepatitis transmission and disease
- Eliminating transmission of vaccine-preventable viral hepatitis
- Reducing viral hepatitis cases associated with drug-use behaviors
- Protecting patients and workers from health-care-associated viral hepatitis
Purpose: Facilitate opportunities to talk through potential activities, challenges, tools, resources, and partnerships related to each priority area.

Discussion questions provided, e.g.,

- What are the best ways to identify persons with chronic viral hepatitis who do not know they are infected? What can your organization do to promote this?

Sample hepatitis planning sheet to prioritize, set timeframes, & measures

Available at www.AIDS.gov/hepatitis
Tools to address viral hepatitis

Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis

Updated
2014-2016

The Patient Protection & Affordable Care Act

111th Congress of the United States
H.R. 3590

MMWR
Morbidity and Mortality Weekly Report
August 17, 2012

Recommendations for the identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965

Hepatitis Testing Day
May 19

integration.samhsa.gov
Resources

• The ABCs of Hepatitis
• TIP 53: Addressing Viral Hepatitis in People with Substance Use Disorders
• Guide to Comprehensive Hepatitis C Counseling and Testing
• NY State Department of Health AIDS Institute: Hepatitis C Rapid Testing Program Implementation Guidelines
Resources

New York University Center for Drug Use and HIV Research
HCV brief:

Harm Reduction Coalition information on HCV prevention
  ● http://harmreduction.org/syringe-access/syringe-access-tools/seps-and-hepatitis-c/

The HCV Advocate

National Viral Hepatitis Roundtable
  ● http://nvhr.org/content/navigating-hepatitis-c-what-patients-need-know-0
  ● http://nvhr.org/content/new-report-hcv-treatment-access-restrictions
Thank You

Questions? jmayas2@mayatech.com